Jeffrey Bryan Carroll

List of Publications by Year
in descending order

31 papers	2,391 citations	331670 21 h-index	434195 31 g-index
39 all docs	39 docs citations	39 times ranked	3236 citing authors

#	Article	IF	Citations
1	Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant Huntingtin. Molecular Therapy, 2011, 19, 2178-2185.	8.2	246
2	CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing Haplogroup. American Journal of Human Genetics, 2009, 84, 351-366.	6.2	204
3	Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease. Journal of Neuroscience, 2009, 29, 2414-2427.	3.6	160
4	Automated deformation analysis in the YAC128 Huntington disease mouse model. NeuroImage, 2008, 39, 32-39.	4.2	150
5	Cholesterol Defect Is Marked across Multiple Rodent Models of Huntington's Disease and Is Manifest in Astrocytes. Journal of Neuroscience, 2010, 30, 10844-10850.	3.6	136
6	Treating the whole body in Huntington's disease. Lancet Neurology, The, 2015, 14, 1135-1142.	10.2	126
7	Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease. NeuroImage, 2008, 41, 243-251.	4.2	115
8	In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides. Molecular Therapy, 2014, 22, 2093-2106.	8.2	115
9	Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Human Molecular Genetics, 2008, 17, 2390-2404.	2.9	112
10	Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Human Molecular Genetics, 2007, 16, 2187-2198.	2.9	106
11	Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiology of Disease, 2007, 26, 189-200.	4.4	97
12	A fully humanized transgenic mouse model of Huntington disease. Human Molecular Genetics, 2013, 22, 18-34.	2.9	93
13	Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients. PLoS ONE, 2014, 9, e107434.	2.5	92
14	Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight, 2019, 4, .	5.0	80
15	Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14. Human Molecular Genetics, 2011, 20, 3356-3365.	2.9	71
16	Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Research, 2020, 48, 10615-10631.	14.5	69
17	Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiology of Disease, 2011, 43, 257-265.	4.4	65
18	Transcriptional regulatory networks underlying gene expression changes in Huntington's disease. Molecular Systems Biology, 2018, 14, e7435.	7.2	55

#	Article	IF	Citations
19	Parvoviral nuclear import: bypassing the host nuclear-transport machinery. Journal of General Virology, 2006, 87, 3209-3213.	2.9	54
20	High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntingtonâ€™s disease CAG knock-in mice across multiple genetic backgrounds. Human Molecular Genetics, 2017, 26, 913-922.	2.9	37
21	Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Molecular Neurodegeneration, 2011, 6, 59.	10.8	30
22	Single-Nucleus RNA-Seq Reveals Dysregulation of Striatal Cell Identity Due to Huntington's Disease Mutations. Journal of Neuroscience, 2021, 41, 5534-5552.	3.6	30
23	HttQ111/+ Huntingtonâ€™s Disease Knock-in Mice Exhibit Brain Region-Specific Morphological Changes and Synaptic Dysfunction. Journal of Huntington's Disease, 2018, 7, 17-33.	1.9	27
24	Huntingtin structure is orchestrated by HAP40 and shows a polyglutamine expansion-specific interaction with exon 1. Communications Biology, 2021, 4, 1374.	4.4	22
25	HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation. PLoS ONE, 2015, 10, e0134465.	2.5	20
26	Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.HttQ111/+ model of Huntingtonâ€™s disease. Scientific Reports, 2017, 7, 41570.	3.3	16
27	Dynamics of huntingtin protein interactions in the striatum identifies candidate modifiers of Huntington disease. Cell Systems, 2022, 13, 304-320.e5.	6.2	15
28	Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntingtonâ€™s disease. PLoS ONE, 2017, 12, e0175968.	2.5	13
29	HDBuzz: empowering patients through accessible education. Trends in Molecular Medicine, 2012, 18, 1-3.	6.7	6
30	Early Detection of Apathetic Phenotypes in Huntingtonâ€™s Disease Knock-in Mice Using Open Source Tools. Scientific Reports, 2018, 8, 2304.	3.3	6
31	Stool is a sensitive and noninvasive source of DNA for monitoring expansion in repeat expansion disease mouse models. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	1